In addition to synthesizing missing imaging data, predicting clinical attributes including mutations in BC driver genes, Estrogen Receptor (ER) status, ER-positive/Human Epidermal growth factor Receptor 2-positive (ER+/HER2+) subtypes, prognosis, and treatment efficacy based on MRIs also played an important role in BC radiogenomic studies [21–24]. This evidence concerns the gene ERBB2 and breast cancer.